Catabasis Pharmaceuticals

Region Nordamerika
ISIN US14875P2065
Sektor Biotechnologie

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit or

Artikel über Catabasis Pharmaceuticals

Titel Autor Datum
Der Tenbagger-Kandidat für 2020!
sharedeals vor über 2 Jahren
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare
sharedeals vor über 3 Jahren